Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Johnson & Johnson, Novartis and Astellas all took part in the first close of a round for oncology therapy developer 28-7 Therapeutics that now stands at $82.8m.

Regenerative medicine spinout LifeSprout is advancing JHU research into a nanofibre-fortified gel that can be injected to repair soft tissue.

OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.

Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.

BGI's gene sequencer spinoff, MGI Tech, has secured $200m in funding from Goldstone Investment, Green Pine Capital and Orient Securities despite a reported $1bn target.

Pfizer, Takeda and Alphabet-backed degenerative disease drug developer Cortexyme priced its initial public offering in the middle of its range to raise $75m.

Corporate joint venture Echo Health Ventures led a $33m funding round that will help fund the home care access platform's expansion in the US.

GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.

TigerMed-backed brain monitor developer Neural Analytics boosted its total funding to $66m in a series C round led by existing investor Alpha Edison.